CFDE Data Portal | Search KANSL1-AS1

	Label	Description
	KANSL1-AS1 associations Collection (Entity type)	Associations for KANSL1-AS1_associations
	KANSL1-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	KANSL1-AS1 Gene (Entity type)	ENSG00000214401 - KANSL1 antisense RNA 1
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876,GSE147877 2 V 7 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 0 V 5 ROMIDEPSIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

KANSL1-AS1 associations

Associations for KANSL1-AS1_associations

KANSL1-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

KANSL1-AS1

ENSG00000214401 - KANSL1 antisense RNA 1

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

A Gene Set from LINCS

GSE147876,GSE147877 2 V 7 ENZALUTAMIDE HUMAN UP

A Gene Set from LINCS

GSE114883 0 V 5 ROMIDEPSIN HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.